Metastatic appendicular soft tissue sarcoma: treatment and survival outcomes of 2,553 patients from the SEER database

Abstract

Introduction: Patients with soft tissue sarcoma (STS) that present with metastasis at diagnosis have a dire prognosis. Within this patient population, we sought to assess: (1) demographic and clinical characteristics, (2) metastatic patterns, (3) treatment strategies, and (4) disease-specific survival (DSS).

Materials and Methods: The SEER database was queried to identify patients with histologically confirmed STS of the pelvis or extremity. Univariate and multivariate analysis was performed using the Cox proportional hazards model. Disease-specific survival (DSS) was analyzed using the Kaplan-Meier method.

Results: A total of 22,683 patients were retrieved, out of which 2,553 (11.3%) had metastasis at diagnosis. Leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, synovial sarcoma, spindle cell sarcoma, and alveolar rhabdomyosarcoma (A-RMS) were the six most common STS presenting with metastasis. Among patients with metastasis, 53.7% and 33.2% of patients had primary tumors located in the lower limb and pelvis, respectively. Lung was the most common site of metastasis in all subtypes except A-RMS, in which bone metastases and lymph node (LN) predominated (85.2% and 62.1%, respectively). Chemotherapy and radiotherapy were associated with higher DSS (HR = 0.788 and HR = 0.755, respectively). Five-year DSS was below 20% in all tumor histologies. Two-year DSS for patients with synchronous lung and liver metastases was 28%.

Conclusion: Although the lung was the most common site of metastasis, metastatic patterns are highly variable depending on tumor histology. Metastatic A-RMS is most commonly presented with regional LN and bone involvement. Disease-specific survival remained poor for patients with metastatic disease at presentation regardless of (neo)-adjuvant radiotherapy or chemotherapy.

Keywords

Soft tissue sarcoma / metastasis / treatment / survival

References

[1] Jemal A,Ward E,Xu J.Cancer statistics, 2007.CA Cancer J Clin2007;57:43-66

[2] Gamboa AC,Cardona K.Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine.CA Cancer J Clin2020;70:200-29

[3] Gonzalez MR,Leon-Abarca JA.Brain metastases in patients with soft-tissue sarcomas: management and survival-a SEER population-based cohort study.J Am Acad Orthop Surg Glob Res Rev2021;5:1-10 PMCID:PMC8500609

[4] Dangoor A,Gerrand C,Whelan J.UK guidelines for the management of soft tissue sarcomas.Clin Sarcoma Res2016;6:20 PMCID:PMC5109663

[5] Von Mehren M,Benjamin RS.Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2018;16:536-63

[6] Kawae Y,Onodera T.Liver metastasis in soft tissue sarcoma at initial presentation.J Surg Oncol2022;126:1074-9

[7] Younis MH,Pretell-Mazzini J.Bone metastasis in extremity soft tissue sarcomas: risk factors and survival analysis using the SEER registry.Musculoskelet Surg2022;106:59-68

[8] Frezza AM,Gronchi A.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.BMC Med2017;15:109 PMCID:PMC5455204

[9] Shah NK,Jones JA.Radiation therapy in metastatic soft tissue sarcoma: from palliation to ablation.Cancers2021;13:4775 PMCID:PMC8508247

[10] Casali PG,Bauer S.Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol2018;29:iv51-67

[11] Haddox CL.Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.Expert Rev Anticancer Ther2020;20:5-8

[12] Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program.Oncologist2003;8:541-52

[13] Gonzalez MR,Portmann-Baracco A,Castillo-Flores S.Appendicular dedifferentiated chondrosarcoma: a management and survival study from the SEER database.J Bone Oncol2022;37:100456 PMCID:PMC9557033

[14] Gonzalez MR,Portmann-Baracco A,Pretell-Mazzini J.Treatment and survival outcomes in metastatic Merkel cell carcinoma: analysis of 2010 patients from the SEER database.Cancer Treat Res Commun2022;33:100665

[15] Ferguson PC,Chung P.Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection.Cancer2011;117:372-9

[16] Krishnan CK,Park JW.Outcome after surgery for extremity soft tissue sarcoma in patients presenting with metastasis at diagnosis.Am J Clin Oncol2018;41:681-6

[17] Tao X,Wu Z,Liu B.Brain metastatic alveolar soft-part sarcoma: clinicopathological profiles, management and outcomes.Oncol Lett2017;14:5779-84 PMCID:PMC5661425

[18] Knebel C,Pohlig F.Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years.BMC Cancer2017;17:410 PMCID:PMC5469180

[19] Skapek SX,Gupta AA.Rhabdomyosarcoma.Nat Rev Dis Primers2019;5:1 PMCID:PMC7456566

[20] Van Gaal JC,Rikhof B.The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study.Anticancer Res2012;32:4485-98

[21] Joshi D,Paidas C,Parham DM.Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children’s oncology group.Pediatr Blood Cancer2004;42:64-73

[22] Akinyemiju T,Waterbor J,Altekruse SF.Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.Cancer Med2018;7:1183-93 PMCID:PMC5911612

[23] Akinyemiju TF,Chavez-Yenter D,Budhwani H.Race/ethnicity and socio-economic differences in breast cancer surgery outcomes.Cancer Epidemiol2015;39:745-51

[24] Lewis SJ,Couture J.Soft tissue sarcomas involving the pelvis.J Surg Oncol2001;77:8-14; discussion 15

[25] Keyzer-Dekker CM,Peterse JL.Adult pelvic sarcomas: a heterogeneous collection of sarcomas?.Sarcoma2004;8:19-24 PMCID:PMC2395600

[26] Brennan MF,Moraco N.Lessons learned from the study of 10,000 patients with soft tissue sarcoma.Ann Surg2014;260:416-21; discussion 421-2 PMCID:PMC4170654

[27] Smith HG,Thomas JM,Strauss DC.Patterns of disease relapse in primary extremity soft-tissue sarcoma.Br J Surg2016;103:1487-96

[28] Jain S,Prieto VG.Molecular classification of soft tissue sarcomas and its clinical applications.Int J Clin Exp Pathol2010;3:416-28 PMCID:PMC2872748

[29] Jaques DP,Casper ES.Hepatic metastases from soft-tissue sarcoma.Ann Surg1995;221:392-7 PMCID:PMC1234589

[30] Smolle MA,Bernhardt GA.Abdominal metastases of primary extremity soft tissue sarcoma: a systematic review.World J Clin Oncol2020;11:74-82 PMCID:PMC7046921

[31] Grimme FAB,van Hillegersberg R.Liver resection for hepatic metastases from soft tissue sarcoma: a nationwide study.Dig Surg2019;36:479-86 PMCID:PMC6878742

[32] Oberlin O,Lyden E.Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.J Clin Oncol2008;26:2384-9 PMCID:PMC4558625

[33] Smith HG,Smith MJF,Strauss DC.Major amputations for extremity soft-tissue sarcoma.Ann Surg Oncol2018;25:387-93

[34] Lindsay AD,Chan CM.Treatment of sarcoma lung metastases with stereotactic body radiotherapy.Sarcoma2018;2018:9132359 PMCID:PMC5901828

[35] Loi M,Baker S.Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.Radiol Med2018;123:871-8

[36] Wiltink LM,Gelderblom H.Treatment strategies for metastatic soft tissue sarcomas.Cancers2021;13:1722 PMCID:PMC8038736